
    
      The safety and effectiveness of the microwave ablation treatment system produced by Suzhou
      Hengrui Hongyuan Medical Technology Co., Ltd. for the ablation treatment of primary liver
      cancer is verified through the implementation of prospective, multi-center, single-group
      target value research. According to the requirements of the trial, 139 patients who were
      diagnosed with primary liver cancer before surgery and met the inclusion criteria without any
      exclusion criteria were selected for treatment of their liver cancer with a microwave
      ablation treatment system, 1 month, 3 months and 6 months after surgery Carry out clinical
      and imaging follow-up to evaluate the safety of the operation and the effect of tumor
      ablation.
    
  